Chronic pain patients enrolled in a statewide medical marijuana program are more likely to reduce their use of prescription drugs than are those patients who don’t use cannabis, according to data published online ahead of print in the Journal of Post-Acute and Long-Term Care Medicine.
Investigators from the University of New Mexico compared prescription drug use patterns over a 24-month period in 83 pain patients enrolled in the state’s medical cannabis program and 42 non-enrolled patients. Researchers reported that, on average, program registrants significantly reduced their prescription drug intake while non-registrants did not.
Specifically, 34 percent of registered patients eliminated their use of prescription drugs altogether by the study’s end, while an additional 36 percent of participants used fewer medications by the end of the sample period.
“Legal access to cannabis may reduce the use of multiple classes of dangerous prescription medications in certain patient populations,” authors concluded. “[A] shift from prescriptions for other scheduled drugs to cannabis may result in less frequent interactions with our conventional healthcare system and potentially improved patient health.”
A pair of studies published in the journal Health Affairs previously reported that medical cannabis access is associated with lower Medicaid expenditures and reduced spending on Medicare Part D approved prescription medications.
Separate studies have reported that patients with legal access to medical marijuana reduce their intake of opioids, benzodiazepines, anti-depressants, migraine-related medications, and sleep aids, among other substances.
An abstract of the study, “Effects of legal access to cannabis on Scheduled II–V drug prescriptions,” appears online here.